Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

The Benefits of Tucatinib in HER2+ Breast Cancer

July 1st 2020

Understanding the HER2CLIMB Trial

July 1st 2020

A Close Look at Tucatinib in HER+ Breast Cancer

July 1st 2020

Treatment for Metastatic Breast Cancer

July 1st 2020

Impact of Recent Clinical Data on Treatment for HER2+ MBC

June 30th 2020

CDK4/6 Inhibitors for Triple-Positive Breast Cancer

June 30th 2020

SOPHIA: Margetuximab + Chemotherapy for RR HER2+ MBC

June 30th 2020

DS-8201 and Tucatinib in HER2+ Metastatic Breast Cancer

June 30th 2020

Treatment Choice for Patient Relapsing With Brain Metastases

June 30th 2020

HER2CLIMB: Brain Metastases Data

June 30th 2020

Biomarker Data After Neoadjuvant Therapy for HER2+ Breast Cancer

June 30th 2020

HER2+ Early Stage Breast Cancer With Residual Invasive Disease

June 30th 2020

KAITLIN: T-DM1/Pertuzumab After Anthracycline-Based Adjuvant Therapy

June 30th 2020

TRAIN-2: Anthracyclines in HER2+ Breast Cancer

June 30th 2020

APHINITY and ExteNET Trials for Early-Stage Breast Cancer

June 30th 2020

HER2+ Early-Stage Breast Cancer

June 30th 2020

Guidelines and Approaches to HER2 Testing for Breast Cancer

June 30th 2020

FDA Approves Fixed-Dose Pertuzumab/Trastuzumab Combo in HER2+ Breast Cancer

June 29th 2020

The FDA has approved a fixed-dose combination of pertuzumab (Perjeta) and trastuzumab (Herceptin) with hyaluronidase, administered via subcutaneous injection in combination with intravenous chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer.

Nivolumab/Ipilimumab Combo Shows Promise in Metaplastic Breast Cancer

June 26th 2020

Sylvia Adams, MD, discusses the cohort 36 findings of the DART trial in metaplastic breast cancer and the evolution of immunotherapy, specifically in this rare breast cancer subtype.

Double PIK3CA Mutations in Breast Cancer Increase Sensitivity to PI3Kα Inhibition

June 24th 2020

Patients with breast cancer who harbor multiple PIK3A-mutant tumors achieved a higher clinical benefit from PI3Kα inhibition compared with single mutant tumors according to response analysis data from the SANDPIPER trial.